Phaseline

Targets › FABB

FABB: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Sep 2028.

Open in Phaseline: the race on FABB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OtsukaQuabodepistat
Mycolic acid biosynthesis inhibitor (FABB inhibitor)
FABBPhase 3Rifampicin-Resistant Pulmonary TuberculosisSep 2028

Conditions

Rifampicin-Resistant Pulmonary Tuberculosis (1)

Modalities

small molecule (1)

Companies

Otsuka (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.